In conclusion, this study suggests that by improving insulin sensitivity a dual PPAR α/γ agonist has the potential to reverse and normalise most of the lipoprotein abnormalities in patients with CKD and chronic renal failure. This evidence concerns the gene INS and chronic kidney disease.